InMed Posts $2.33M Q1 Loss, Cash Down to $1.0M, Nasdaq Cure Deadline Extended to March 15, 2027
INM has more than doubled off its 52-week low of $0.575 on elevated volume (2.5× avg).
Summary
InMed burned through half its cash in the September quarter, leaving $1.0 million and runway only into mid-November — one day before a shareholder vote on the Mentari merger that would bring roughly US$490 million in expected financing. Nasdaq accepted its compliance plan and extended the equity cure deadline to March 15, 2027.
Key Events · Earnings and Guidance · INM
-
Q1 FY2027 Loss Widens to $2.33M
Net loss was $2.33 million for the quarter ended September 30, 2026 versus $1.73 million a year earlier, as G&A rose to $1.8 million from $1.2 million while R&D fell to $0.2 million from $0.6 million on reduced activity ahead of the merger.
-
Cash Falls to $1.0M, Runway to Mid-November
Cash and cash equivalents dropped to $1,094,488 at September 30, 2026 from $2,194,413 at June 30, 2026; management expects available cash to fund operations only into mid-November. Shareholders' equity turned negative at $(1,199,396).
-
Nasdaq Accepts Plan, Deadline March 15, 2027
Nasdaq accepted InMed's October 30, 2026 compliance plan and set March 15, 2027 to regain the $2.5 million minimum shareholders' equity requirement; the company expects the Mentari merger and associated pre-closing financing to cure the deficiency.
-
November 4 Vote on Mentari Reverse Merger
The annual general and special meeting is scheduled for November 4, 2026, where shareholders vote on the merger with Mentari Therapeutics; Mentari has announced private placements totaling approximately US$490 million in expected gross proceeds, expected to fund operations into 2029.
Analysis · INM · Life Sciences
With roughly six weeks of cash left — $1.0 million at September 30 versus $2.2 million three months earlier, and management guiding runway only into mid-November — the November 4 shareholder vote on the Mentari reverse merger becomes a survival question rather than a strategic preference. The deal brings roughly US$490 million in expected Mentari private placement proceeds and is the company's stated path to regaining Nasdaq's $2.5 million equity requirement. Genuinely new good news: Nasdaq accepted the compliance plan on October 30 and pushed the cure deadline out to March 15, 2027, buying time the balance sheet alone would not have provided. If shareholders vote the merger down, the company is out of cash and out of compliance with no disclosed alternative financing.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 32.4% of the 2240 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $0.58 to $2.33. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.